Loading organizations...

Condor Software, Inc. is a technology company.
Condor Software provides a financial intelligence platform tailored for the life sciences, centralizing R&D finance management. The platform automates accruals, forecasting, and budgeting by unifying clinical, operational, and financial data. It offers AI-powered insights for scenario modeling and compliance, granting biopharma teams superior control over complex clinical trial financials.
Founded by Jen Kyle, the company emerged from her pharmaceutical industry experience, observing critical financial inefficiencies in clinical development. Kyle realized fragmented processes and outdated systems hindered therapeutic progress. This insight led her to build Condor, assembling experts to create an enterprise-grade financial cloud, replacing manual efforts to accelerate life-changing treatments.
Condor serves diverse life sciences clients, including biopharma companies, MedTech firms, and Contract Research Organizations. Its mission is to empower innovators by optimizing R&D finance, expediting new treatments to patients. Condor's vision focuses on eliminating clinical research financial inefficiencies, directing resources to scientific advancements.
Condor Software, Inc. has raised $54.0M across 3 funding rounds.
Condor Software, Inc. has raised $54.0M in total across 3 funding rounds.
Condor Software, Inc. is a technology company that builds specialized finance and accounting software tailored for the biopharmaceutical industry, particularly focused on clinical trial financial management. Its flagship product, the Condor Cloud, automates clinical accruals, budget tracking, forecasting, and scenario planning, enabling finance, accounting, clinical operations, and FP&A teams to manage R&D finances with greater speed, accuracy, and control. The platform integrates seamlessly with major clinical and accounting systems, providing real-time financial insights that help biopharma companies optimize clinical portfolios and accelerate decision-making. Condor serves biotech and pharmaceutical companies, including publicly traded firms and Big 4 accounting firms, addressing the complex financial challenges in clinical research and development[1][2][3][4].
Founded in 2020 by Jennifer (Jen) Kyle, a CPA and financial consultant with deep experience in biopharma finance, Condor Software emerged from her firsthand observation of the inefficiencies and risks caused by manual spreadsheets, disconnected systems, and complex accrual processes in R&D financial management. Motivated by a personal connection to the impact of clinical trials and a desire to help bring life-saving treatments to patients faster, Kyle collaborated with industry leaders and Big 4 firms to design an enterprise-grade financial cloud solution purpose-built for biopharma. Early traction included adoption by leading biopharma companies and successful integration with clinical vendors, culminating in the launch of the Condor Cloud platform that revolutionizes clinical trial financial workflows[1][2].
Condor Software rides the growing trend of digital transformation in life sciences, particularly the urgent need for integrated, automated financial management in clinical R&D. With global biopharma R&D spending exceeding $300 billion annually, the timing is critical as companies seek to reduce costly inefficiencies and accelerate drug development timelines. Market forces such as increasing clinical trial complexity, regulatory demands, and the push for data-driven decision-making favor Condor’s cloud-based, AI-enhanced platform. By streamlining financial workflows and improving transparency, Condor influences the broader ecosystem by enabling biopharma companies to allocate resources more strategically and bring therapies to market faster[1][2][4].
Looking ahead, Condor Software is poised to expand its product suites and deepen its integration capabilities, further embedding itself as the financial backbone for biopharma R&D. Trends such as increased adoption of cloud computing, AI-driven analytics, and the growing importance of financial agility in clinical development will shape its evolution. As the company scales, its influence may extend beyond finance teams to broader clinical operations and strategic portfolio management, reinforcing its mission to accelerate life-saving treatments. Condor’s continued innovation and industry partnerships position it as a critical enabler in the future of biopharma financial intelligence[1][2][4].
Condor Software, Inc. has raised $54.0M in total across 3 funding rounds.
Condor Software, Inc.'s investors include Alex Leibowitz, 645 Ventures, Bramalea Partners, Felicis Ventures, Pamir Ventures, Prebys Ventures Fund, SNR, Accel, Blackbird Ventures Australia, Stewart Butterfield, Insight Partners, Richard Matus.
Condor Software, Inc. has raised $54.0M across 3 funding rounds. Most recently, it raised $24.0M Condor Software - Series A in March 2026.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 18, 2026 | $24.0M Condor Software - Series A | Alex Leibowitz | 645 Ventures, Bramalea Partners, Felicis Ventures, Pamir Ventures, Prebys Ventures Fund, SNR |
| Feb 1, 2022 | $6.0M Seed | Accel, Blackbird Ventures Australia, Felicis Ventures, Stewart Butterfield | |
| $24.0M Condor Software Series A Round | Insight Partners, Alex Leibowitz, Richard Matus |